Chalcone-templated Hsp90 inhibitors and their effects on gefitinib resistance in non-small cell lung cancer (NSCLC)
Authors:
- 21 October 2016
- journal article
- research article
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 40 (1) , 96-105
Abstract
The molecular chaperone Hsp90 has emerged as an attractive cancer therapeutic target due to its role in cellular homeostasis by modulating the stabilization and maturation of many oncogenic proteins. In this study, we designed and synthesized a series of Hsp90 inhibitors that hybridized NVP-AUY992 (2) and PU3 (3) in the chalcone scaffold using a structure-based approach. Our results indicate that compound 1g inhibited the proliferation of gefitinib-resistant non-small cell lung cancer (H1975) cells, downregulated the expression of client proteins of Hsp90 including EGFR, MET, Her2 and Akt, and up-regulated the expression of Hsp70. The compound 1g represents a new class of Hsp90 inhibitors with a chalcone structure. The design, synthesis, and evaluation of 1g are described herein.Keywords
This publication has 24 references indexed in Scilit:
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Targeted cancer therapiesNature Reviews Drug Discovery, 2010
- Targeting HSP90 for cancer therapyBritish Journal of Cancer, 2009
- 4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of CancerJournal of Medicinal Chemistry, 2007
- Local Recurrence Following Initial Resection of NSCLCThe Cancer Journal, 2006
- EGFRMutation and Resistance of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2005
- Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic PathwaysScience, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Structure-Activity Relationships in Purine-Based Inhibitor Binding to HSP90 IsoformsChemistry & Biology, 2004
- The Hallmarks of CancerCell, 2000